HEALTH: Summary of Oct 27, 2026

By · Published on

Illustration of a medicine bottle and pills
AI-generated illustration; does not depict the actual event.

A study showing that a third of young American adults turn to chatbots for advice on drugs and alcohol leads today’s health summary, followed by new expert advice on weight-loss drugs and eating disorders, the killing of a nurse in Congo’s Ebola outbreak, a cancer biobank network in Nigeria and research on aspirin and dementia.

One in three young American adults ask chatbots about drugs and alcohol, study finds

About a third of young adults in the United States have used chatbots to look up information about drugs and alcohol, according to a Rutgers University study published in JMIR Formative Research. The online survey of 995 people aged 18 to 29, carried out in April, found that 32 per cent had used tools such as ChatGPT, Google Gemini or Meta AI for such questions, and nearly half of them did so at least once a month.

Most users wanted to understand the risks and consequences of substance use, around half asked about specific drugs, including doses, and 35 per cent explored addiction. Nearly all of them, 93 per cent, also searched Google for the same purpose. The lead author, Mireia Triguero Roura, warned that the tools could lead young people towards misinformed or risky behaviour, while the researchers said future work should test how accurate chatbot answers are.

Users rated the chatbots highly, giving them an average trust score of 3.66 out of five for questions about substances. Black respondents were more likely than white respondents to use them for this purpose, and men about twice as likely as women, gaps the authors said may reflect differences in access to healthcare, stigma and trust. Rutgers, chartered in 1766, is the State University of New Jersey and one of nine colonial colleges.


Experts urge eating disorder screening before prescribing weight-loss drugs

An international panel has recommended that everyone should be screened for current or past eating disorders before starting treatment with GLP-1 drugs such as semaglutide and tirzepatide. The consensus, published in World Psychiatry, was drawn up by 45 experts and people with personal experience of eating disorders, and concludes that the drugs can bring benefits but carry real risks for people who have or are vulnerable to these conditions.

The panel agreed unanimously that the drugs should be avoided in people currently diagnosed with atypical anorexia nervosa, or with bulimia nervosa involving strict dietary restriction, and urged caution for those with a history of these disorders. It also called for ongoing monitoring during treatment and for psychological therapy alongside the drugs. Reports have described relapses into extreme dieting among people with a history of anorexia who were taking the medicines.

Evidence that the drugs help people with binge eating disorder remains limited, and the best-designed study found no fall in binge episodes on liraglutide compared with a placebo. GLP-1 receptor agonists mimic a gut hormone that lowers blood sugar and appetite. First developed for type 2 diabetes, some have since been approved for obesity, and they are being studied for liver disease and addictions. The panel warned that quieter thoughts about food are not the same as recovery.


Nurse killed by a mob while raising Ebola awareness in eastern Congo

A nurse was killed and a teacher wounded when a crowd armed with machetes and batons attacked them in the town of Bafwasende, in Congo’s Tshopo province, where both were working to raise awareness of the Ebola outbreak. According to a memo seen on Monday, people building a house nearby accused the pair of spreading the virus by contaminating water, before young men joined the attack on Friday afternoon. The nurse died at the scene.

Health workers in Bafwasende are now sleeping at the general hospital under police guard, and the army was briefly deployed to the area. Days earlier, another community worker was attacked and his house set on fire. Julien Harneis, the senior United Nations Ebola coordinator, said the killing was a loss to the response and an even greater loss to patients, as misinformation continues to fuel attacks on hospitals, vehicles and staff.

Tshopo is one of eight Congolese provinces battling the outbreak, which has reached 9,964 confirmed cases since it was declared in May, with a fatality rate of around 48.6 per cent. It is caused by the Bundibugyo virus, a species closely related to Zaire ebolavirus, named after the Ugandan district where it was first identified. The virus also caused outbreaks in 2007 and 2012, and this year’s epidemic is the fastest-growing Ebola outbreak on record.


Nigeria begins building a national network of cancer biobanks

Nigeria’s National Institute for Cancer Research and Treatment has started putting in place a national cancer biobank network with BioVana, a health data company, linking eight federal hospitals across the country’s six geopolitical zones. The first phase aims to collect and catalogue 10,000 cancer samples, with a longer-term goal of 100,000 by 2028, and builds on an agreement signed by the two organisations in 2025.

The institute will lead and oversee the network, while BioVana will handle the technical side, including digital systems, common standards for samples and data, and training. The project’s backers say it is one of the first nationally coordinated networks of its kind in Africa, and should make it easier to run larger studies across several hospitals and to develop diagnostics and treatments suited to Nigerian patients.

In 2024 Nigeria had an estimated 152,000 cancer cases, and deaths topped 90,000, and Africa reported more than 1 million new cases in 2020, a number expected to double within 15 years. Biobanks store biological samples, usually human, for use in research, and have become important for genomics and personalised medicine, although they have also raised questions about privacy and research ethics.


Low-dose aspirin linked to lower dementia risk in people with one genetic profile

Daily low-dose aspirin was linked to a 70 per cent lower risk of dementia among older people whose genes point to high platelet counts, researchers at Monash University in Australia have reported. Among participants in the top 20 per cent of this genetic score, 1 per cent of those taking aspirin developed dementia, compared with 3.3 per cent of those on a placebo. The study was published in Alzheimer’s & Dementia.

The benefit came at a cost: major bleeding in the same group was about twice as common with aspirin, at 4.4 per cent against 2.1 per cent. The lead author, Peter Fransquet, said earlier trials had found that aspirin did not prevent dementia overall, but the new results suggested there may be more to the story. The team said the finding must be confirmed in other studies and in a dedicated trial.

The analysis used genetic data from 13,541 volunteers in ASPREE, a large trial in which healthy older adults took 100 mg of aspirin a day or a placebo and which found no overall effect on dementia. About 57 million people lived with dementia in 2021, with nearly 10 million new cases a year. Dementia is a progressive decline in memory and thinking that affects everyday life, and Alzheimer’s disease is its most common form.

In this topic